Key result
Bile acid receptor modulation reduces blood pressure in preclinical models via upstream RAAS regulation.
Why the study?
The study was conducted to clarify cross-system regulatory intersections and generate testable hypotheses linking bile acid receptor signaling, RAAS biomarkers, and chloride/bicarbonate trends.
Bile acid signaling via FXR and TGR5 may act as an upstream modulator of the renin-angiotensin-aldosterone system, offering a novel mechanistic framework for understanding certain blood pressure and acid-base disturbances.
Answers are grounded in this paper and cite their sources.
Should not change RAAS management; leaves open FXR/TGR5 modulation as upstream target for future trials.
The renin–angiotensin–aldosterone system (RAAS) is classically described as a renal pressure–volume regulatory cascade initiated by renin release and propagated through angiotensin signaling. In parallel, bile acids function as systemic signaling molecules acting through the nuclear receptor farnesoid X receptor (FXR; NR1H4) and the membrane receptor TGR5 (GPBAR1), with established roles in hepatic, vascular, and renal physiology. Increasing preclinical evidence indicates that renal and vascular FXR activation attenuates hypertensive phenotypes, modulates nitric oxide signaling, and alters RAAS-related pathways. Direct suppression of renin gene transcription is demonstrated primarily in animal and cell models, whereas human data more clearly support FXR-mediated shifts in vascular receptor balance (e.g., AT2R regulation) and renal injury pathways commonly driven by RAAS activation. This note proposes a mechanistic continuity model: bile acid receptor signaling may function as an upstream modulator of RAAS tone, with downstream implications for renal tubular transport, chloride handling, and acid–base balance. While causal human renin-transcription evidence remains limited, the convergence of hepatic–vascular–renal FXR/TGR5 signaling provides a plausible framework for understanding oscillatory blood pressure patterns and hyperchloremic, non–anion gap metabolic disturbances observed in certain clinical phenotypes. The objective is not to redefine RAAS biology, but to clarify cross-system regulatory intersections and generate testable hypotheses linking bile acid signaling, RAAS biomarkers, and chloride/bicarbonate trends. Related WorkThis mechanistic note aligns with a growing body of research examining cross-talk between bile acid receptor signaling and cardiovascular–renal regulation. It also situates within a broader systems framework exploring electrolyte regulation, RAAS modulation, and chloride-dominant acid–base patterns. Expanded integrative modeling of hierarchical endocrine and fluid regulatory dynamics is developed in related preprints by the author; however, the present paper is intended as a standalone physiologic continuity analysis grounded in established literature.
No takes yet. Share an insight, caveat, or question.
Beth Ann Martell (2026) conducted a review in Humans and animal models with hypertension or altered RAAS tone relevant to bile acid receptor signaling. FXR/TGR5-active bile acid receptor agonists or bile acid signaling modulation vs. Placebo or baseline/no treatment was evaluated on Blood pressure changes and RAAS marker levels (renin, aldosterone) associated with modulation of bile acid receptor signaling. Bile acid receptor signaling modulation is a credible upstream modulator of RAAS tone, with preclinical models showing antihypertensive effects and vascular receptor remodeling in systems relevant to blood pressure regulation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: